Phaim's lead asset is in type 1 diabetes with pre-clinical results showing that our immunomodulator DMX4001 demonstrates excellent promise. If we are able to demonstrate similar results in our clinical stage studies, our therapy may potentially take away the need for daily insulin injections, with psoriasis our next area of focus.

Phaim Pharma has successfully achieved the following significant clinical development milestones: completed a comprehensive pre-clinical trial which included 4 different murine models to test for toxicity, impact on disease onset, and safety for type 1 diabetes

• manufactured this novel drug (DMX4001) for both the animal and human study and to GMP standards (Good manufacturing practice)

• validated assays for testing the above GMP batch

• demonstrated drug stability developed a drug pipeline that is scaleable and able to support manufacture past the clinical trial • engaged a regulatory contractor to enable MHRA/FDA approval

• Contracted a CMC specialist Engaged with the UK-based 1DM consortium that is the UK network of T1DM clinical trials centres to perform the UK arm of the Phase 1 study Established a clinical network of diabetic centres leveraging collective knowledge and dovetailing into diabetes support care to recruit participants into this novel clinical trial

• secured a comprehensive worldwide patent portfolio for T1D as well as other autoimmune disease treatments

Phaim Pharma has a full, world-wide patent portfolio in:

• autoimmune therapeutics

• autoimmune diagnostics

• autoimmune prognostics

• Type 1 Diabetes novel preventative therapy Accolades:

• UK Business Angel finalist for best covid response 2021

• OBN awards finalist for one to watch 2022

• Recognised as Department of International Trade 'Innovative Showcase 2023' company- Arab Health 2023

• Innovate UK grant to support proof of concept studies

• Innovate UK grant for an internal IP audit and implementation of findings